Laurion Capital Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Laurion Capital Management’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,933	Closed	-$22.8K	–	717
2023 Q1	$22.8K	Hold	1,933	–	–	﹤0.01%	420
2022 Q4	$27.8K	Hold	1,933	–	–	﹤0.01%	393
2022 Q3	$97K	Hold	1,933	–	–	﹤0.01%	450
2022 Q2	$165K	Hold	1,933	–	–	﹤0.01%	389
2022 Q1	$292K	Hold	1,933	–	–	﹤0.01%	440
2021 Q4	$578K	Hold	1,933	–	–	0.01%	406
2021 Q3	$754K	Sell	1,933 -67	-3%	-$28.6K	﹤0.01%	536
2021 Q2	$844K	Sell	2,000 -67	-3%	-$29K	﹤0.01%	459
2021 Q1	$986K	Buy	+2,067	New	+$1.05M	0.01%	500

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Laurion Capital Management's FNCH Position: Q2 2023 in Review

Laurion Capital Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 1,933 shares — an estimated $22.8K sold.

Laurion Capital Management first reported a position in FNCH in Q1 2021 and held it in 9 quarters. The position peaked at $986K in Q1 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

Laurion Capital Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Laurion Capital Management sold 1,933 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $22.8K.
Laurion Capital Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Laurion Capital Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $986K in Q1 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.